Expanded FDA Approval of CAMZYOS® (mavacamten) for Symptomatic Obstructive Hypertrophic Cardiomyopathy in Patients 30 kg and Above
Bristol‑Myers Squibb (BMY) has announced that the United States Food and Drug Administration (FDA) has granted approval for an expanded indication of its cardiac myosin inhibitor, CAMZYOS® (mavacamten), to treat symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in both adult and pediatric patients weighing at least 30 kg. This development follows the positive results of the Phase 3 SCOUT‑HCM trial and represents a significant advance for a patient population that has historically faced limited therapeutic options.
Clinical Evidence Supporting the New Indication
| Study | Population | Key Efficacy Outcomes | Safety Profile |
|---|---|---|---|
| SCOUT‑HCM Phase 3 | Adults and adolescents (≥ 12 y) with symptomatic oHCM | • Significant reduction in left‑ventricular outflow‑tract (LVOT) gradients (mean decrease of 35 mmHg). • Improvement in peak oxygen consumption (VO₂ peak) by 2.4 mL kg⁻¹ min⁻¹. • Enhanced New York Heart Association (NYHA) functional class (≥ 1‑class improvement in 70 % of patients). | • No new safety signals relative to the adult population. • Adverse events comparable to those observed in earlier studies (primarily mild–moderate palpitations, arthralgia, and transient declines in left‑ventricular ejection fraction). |
| Long‑Term Extension Studies | Patients with oHCM (≥ 18 y) | • Sustained LVOT gradient reduction and functional gains for up to 5 years. • No evidence of progressive myopathy or cardiomyopathy worsening. | • No increase in serious adverse events over the extension period. |
The clinical data demonstrate that mavacamten effectively reduces the mechanical obstruction characteristic of oHCM while improving patients’ exercise capacity and overall functional status. Importantly, the safety profile observed in the pediatric subset of SCOUT‑HCM was consistent with that in adults, reinforcing the drug’s tolerability across age groups.
Regulatory Pathway and Global Context
The FDA’s approval followed a comprehensive review of the SCOUT‑HCM trial data, including subgroup analyses of patients ≥ 30 kg. The agency emphasized the absence of new safety signals and the robustness of the efficacy data. BMY’s existing approvals for CAMZYOS® in adults across multiple markets—including Europe, Canada, and Japan—provide a foundation for streamlined regulatory submissions in other jurisdictions. Regulatory authorities in the European Union, Canada, and the Australian Therapeutic Goods Administration have already begun reviewing the pediatric data, with anticipated approvals in the coming 12–18 months.
Practical Implications for Patient Care
- Expanded Treatment Options
- The approval extends a disease‑modifying therapy to children and adolescents with symptomatic oHCM, a group traditionally managed with surgical myectomy or septal ablation.
- Patients who previously required invasive procedures may now have a pharmacologic alternative, potentially reducing procedural risks and healthcare costs.
- Clinical Decision-Making
- Clinicians should evaluate baseline LVOT gradients, functional status, and weight to determine eligibility.
- Monitoring protocols, including echocardiographic assessment of LVOT gradients and regular safety labs (complete blood count, liver function tests), are essential to detect early signs of reduced ejection fraction or hematologic changes.
- Health System Considerations
- The cost of mavacamten must be weighed against the potential savings from avoided surgical interventions and hospitalizations.
- Insurance coverage decisions should consider the drug’s evidence‑based benefit in reducing hospital admissions for heart failure exacerbations associated with oHCM.
Conclusion
The FDA’s approval of CAMZYOS® for symptomatic obstructive hypertrophic cardiomyopathy in patients weighing 30 kg or more represents a milestone in cardiovascular therapeutics. By providing a clinically validated, non‑surgical option for pediatric and adolescent patients, Bristol‑Myers Squibb addresses a critical unmet need and expands the therapeutic landscape for this challenging disease. Continued post‑marketing surveillance and real‑world evidence will further clarify long‑term outcomes and inform optimal integration of mavacamten into routine cardiology practice.
